newsfilter
← Latest News
GlobeNewswire·

Cellect Biotechnology Reports Top Line Data from Phase 1/2 Clinical Trial

Tel Aviv, Israel, April 19, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, today announced positive data from the Company's open label Phas